George Kemble

2.5k citations

36 papers · 1.8k indexed · 2 hit papers · h-index 19

Impact in

Cancer Research top 2%
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
Biochemistry top 5%
- Lipid metabolism and biosynthesis

Papers in

Cancer Research 25
- Cancer, Lipids, and Metabolism 24
- Cancer, Hypoxia, and Metabolism 18
Epidemiology 11
- Herpesvirus Infections and Treatments 6
- Cytomegalovirus and herpesvirus research 6
- Liver Disease Diagnosis and Treatment 3

Co-authors: Douglas Buckley Timothy S. Heuer Zhaoti Wang William McCulloch Marie O’Farrell Marina Fridlib Julie Lai Richard Ventura
Journals: Cancer Research (9 papers)Journal of Clinical Oncology (3 papers)The Journal of Infectious Diseases (3 papers)Molecular Cancer Therapeutics (2 papers)EBioMedicine (2 papers)
Partner nations: United States United Kingdom Hong Kong

In The Last Decade

George Kemble

36 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial 2021 · 163 citations

Peers

Countries citing papers authored by George Kemble

Since Specialization

Citations

This map shows the geographic impact of George Kemble's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Kemble with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Kemble more than expected).

Fields of papers citing papers by George Kemble

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George Kemble. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Kemble. The network helps show where George Kemble may publish in the future.

Co-authors

The 25 scholars most cited alongside George Kemble, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with George Kemble Line = papers co-authored together George Kemble links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models Scientific Reports ·Marie O’Farrell, G M Duke, R. Webster Crowley, Douglas Buckley, Eduardo B. Martins, Dipankar Bhattacharya, Scott L. Friedman, George Kemble	2022	66
2	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells Cell Death and Disease ·Barbara Schroeder, Thomas Wozniak, Ingrid Espinoza, Daryna Dehtiar, Zeng Hu, John C. Beyke, Kevin M. Regan, Elisabet Cuyàs, X. Wei Meng, Sara Verdura, Yang Jiang, Paula A. Schneider, Karen S. Flatten, George Kemble, Joan Montero, Scott H. Kaufmann, Javier A. Menéndez, Ruth Lupu	2021	62
3	First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors EClinicalMedicine ·Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Farshad Ostovar-Sirjani, Shubham Pant, Arthur E. Frankel, Peter Schmid, Kathleen N. Moore, William McCulloch, Katharine Grimmer, Marie O’Farrell, George Kemble, Howard A. Burris Hit paper breakdown →	2021	192
4	Fatty Acid Synthase Inhibitor TVB‐2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities Hepatology ·Majid Mufaqam Syed‐Abdul, Elizabeth J. Parks, Ayman H. Gaballah, Daniel Saad Nogueira Nunes, Ghassan M. Hammoud, George Kemble, Douglas Buckley, William McCulloch, Camila Manrique‐Acevedo	2019	97
5	Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer Oncotarget ·Yekaterina Y. Zaytseva, Piotr Rychahou, 柏发友, Timothy Scott, Robert M Flight, Ji Tae Kim, Jennifer W. Harris, Jinpeng Liu, Chi Wang, Andrew J. Morris, Theru A. Sivakumaran, Teresa W.‐M. Fan, Hunter Moseley, Tianyan Gao, Eun Y. Lee, Heidi L. Weiss, Timothy S. Heuer, George Kemble, Mark B. Evers	2018	97
6	Genomic analysis of chimeric human cytomegalovirus vaccine candidates derived from strains Towne and Toledo Virus Genes ·Nicolás M. Suárez, Betty Lau, George Kemble, Isac Fogaça, Edward S. Mocarski, Gavin W. G. Wilkinson, Stuart P. Adler, Michael A. McVoy, Andrew J. Davison	2017	10
7	Fatty acid synthase – Modern tumor cell biology insights into a classical oncology target Pharmacology & Therapeutics ·Douglas Buckley, Gregory Duke, Timothy S. Heuer, Marie O’Farrell, Allan S. Wagman, William McCulloch, George Kemble	2017	151
8	Abstract P6-11-09: Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel Cancer Research ·K Khajanchi Bijay, Gerald S. Falchook, Manish R. Patel, J. R. Infante, H-T. Arkenau, Soung Won Jung, Erkut Borazanci, Paolo del C. Battán, Kathleen N. Moore, Peter Schmid, Xian-feng, Suzanne F. Jones, William McCulloch, George Kemble, Karen Grimmer, Howard A. Burris	2017	14
9	A phase 2 study to determine the efficacy and safety of TVB-2640 in combination with bevacizumab in patients with first relapse of high grade astrocytoma. Journal of Clinical Oncology ·Don Luckwaldt, Yan Hao, George Kemble, William McCulloch, Andrew Brenner	2017	4
10	FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression EBioMedicine ·Timothy S. Heuer, Richard Ventura, Kasia Mordec, Julie Lai, Marina Fridlib, Douglas Buckley, George Kemble	2016	103
11	A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus–Seronegative Men The Journal of Infectious Diseases ·Stuart P. Adler, Nicola D. Arbuckle, Isac Fogaça, Michael A. McVoy, Daniel E. Nixon, Stanley A. Plotkin, Edward S. Mocarski, Josephine H. Cox, Patricia Fast, R. Messerli, Susan Murray, Ann B. Hill, George Kemble	2016	46
12	Abstract 1010: Evaluation of small-molecule FASN inhibitors in preclinical models of colorectal cancer Cancer Research ·Yekaterina Y. Zaytseva, Piotr Rychahou, Tianyan Gao, Eun Y. Lee, Heidi L. Weiss, Timothy S. Heuer, George Kemble, B. Mark Evers	2016	2
13	Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression EBioMedicine ·Richard Ventura, Kasia Mordec, Joanna Waszczuk, Zhaoti Wang, Julie Lai, Marina Fridlib, Douglas Buckley, George Kemble, Timothy S. Heuer	2015	234
14	Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses PLoS ONE ·Yamini M. Ohol, Zhaoti Wang, George Kemble, Gregory Duke	2015	54
15	Abstract 2675: Biomarker and PK/PD analyses of first in class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients Cancer Research ·Marie O’Farrell, R. Webster Crowley, Timothy S. Heuer, Wen Xiao-xia, Chris Rubino, William McCulloch, George Kemble	2015	2
16	Abstract B13: Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients Molecular Cancer Therapeutics ·Marie O’Farrell, R. Webster Crowley, Timothy S. Heuer, Marina Fridlib, Wen Xiao-xia, William McCulloch, George Kemble	2015	1
17	A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimeric Vaccines The Journal of Infectious Diseases ·Thomas C. Heineman, Mark R. Schleiss, David I. Bernstein, Richard R. Spaete, Lihan Yan, G M Duke, Mark N. Prichard, Zhaoti Wang, Vasilis E. Banikas, Margaret Sharp, Nicola P. Klein, Ann M. Arvin, George Kemble	2006	77
18	Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs Vaccine ·Mark N. Prichard, Ravi Kaiwar, Yendoutie Nakorgou, Debra C. Quenelle, Deborah J. Collins, Earl R. Kern, George Kemble, Richard R. Spaete	2005	50
19	Development of an efficient fluorescence-based microneutralization assay using recombinant human cytomegalovirus strains expressing green fluorescent protein Journal of Virological Methods ·Zhaoti Wang, Chengjun Mo, George Kemble, Gregory Duke	2004	17
20	Persistent and Selective Deficiency of CD4+ T Cell Immunity to Cytomegalovirus in Immunocompetent Young Children The Journal of Immunology ·Wenwei Tu, Sharon Chen, Margaret Sharp, Nijsiri Ruangrungsia, Yuqi Pang, Noga Gal, Holden T. Maecker, Tyson H. Holmes, Zhaoti Wang, George Kemble, Stuart P. Adler, Ann M. Arvin, David B. Lewis	2004	153

About George Kemble

George Kemble is a scholar working on Cancer Research, Epidemiology, Molecular Biology, Virology and Animal Science and Zoology, having authored 36 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer, Lipids, and Metabolism (24 papers), Cancer, Hypoxia, and Metabolism (18 papers), Peroxisome Proliferator-Activated Receptors (12 papers), Herpesvirus Infections and Treatments (6 papers), Cytomegalovirus and herpesvirus research (6 papers), Metabolomics and Mass Spectrometry Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Liver Disease Diagnosis and Treatment (3 papers). The work is most often cited by research in Cancer Research (895 citations), Biochemistry (154 citations), Epidemiology (644 citations), Molecular Biology (851 citations) and Virology (53 citations). George Kemble has collaborated with scholars based in United States, United Kingdom and Hong Kong. Frequent co-authors include Douglas Buckley, Timothy S. Heuer, Zhaoti Wang, William McCulloch, Marie O’Farrell, Marina Fridlib, Julie Lai, Richard Ventura, Kasia Mordec and Gregory Duke. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, The Journal of Infectious Diseases, Molecular Cancer Therapeutics and EBioMedicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact